Fortress Biotech (NASDAQ:FBIO – Get Free Report) is one of 894 public companies in the “Pharmaceuticals” industry, but how does it contrast to its rivals? We will compare Fortress Biotech to similar companies based on the strength of its risk, valuation, dividends, earnings, profitability, institutional ownership and analyst recommendations.
Analyst Recommendations
This is a breakdown of current ratings and recommmendations for Fortress Biotech and its rivals, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Fortress Biotech | 1 | 1 | 2 | 0 | 2.25 |
| Fortress Biotech Competitors | 7845 | 13798 | 25820 | 1039 | 2.41 |
Fortress Biotech currently has a consensus price target of $17.00, indicating a potential upside of 891.25%. As a group, “Pharmaceuticals” companies have a potential upside of 25.36%. Given Fortress Biotech’s higher probable upside, analysts plainly believe Fortress Biotech is more favorable than its rivals.
Profitability
This table compares Fortress Biotech and its rivals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Fortress Biotech | 163.32% | 83.47% | 42.98% |
| Fortress Biotech Competitors | -2,400.61% | -215.91% | -15.58% |
Earnings and Valuation
This table compares Fortress Biotech and its rivals top-line revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Fortress Biotech | $63.26 million | $6.82 million | 0.75 |
| Fortress Biotech Competitors | $3.55 billion | $3.17 billion | 559.00 |
Fortress Biotech’s rivals have higher revenue and earnings than Fortress Biotech. Fortress Biotech is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Insider and Institutional Ownership
96.5% of Fortress Biotech shares are owned by institutional investors. Comparatively, 32.7% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 28.5% of Fortress Biotech shares are owned by company insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Risk & Volatility
Fortress Biotech has a beta of 1.27, meaning that its stock price is 27% more volatile than the S&P 500. Comparatively, Fortress Biotech’s rivals have a beta of -0.05, meaning that their average stock price is 105% less volatile than the S&P 500.
Summary
Fortress Biotech beats its rivals on 7 of the 13 factors compared.
Fortress Biotech Company Profile
Fortress Biotech, Inc. is a biopharmaceutical company that develops and commercializes prescription medicines through a network of subsidiaries and affiliated companies. Its approach includes advancing drug candidates, acquiring or licensing development and commercialization rights, and building companies around selected products and programs. The company’s activities span areas including oncology, dermatology, rare diseases and immunology. Its portfolio has included marketed dermatology medicines such as Qbrexza, Amzeeq and Zilxi, as well as investigational therapies at various stages of development.
Receive News & Ratings for Fortress Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fortress Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
